NASDAQ:SNOA - Sonoma Pharmaceuticals Stock Price, Price Target & More

$3.94 +0.09 (+2.34 %)

(As of 04/22/2018 12:27 PM ET)

Previous Close$3.94

Today's Range$3.81 - $3.95

52-Week Range$3.50 - $7.75

Volume74,305 shs

Average Volume303,519 shs

Market Capitalization$18.69 million

P/E RatioN/A

Dividend YieldN/A

Beta1.31

About Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. Its products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis. The company's Microcyn medical devices are used for cleaning, debridement, lubricating, moistening, and dressing of acute and chronic wounds in tissue care management. It also operates a microbiology contract testing laboratory that offers consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Sonoma Pharmaceuticals, Inc. sells its products directly to end users, as well as to distributors; and through in-house sales force and call center to hospitals, physicians, nurses, and other healthcare practitioners. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:SNOA

CUSIPN/A

Webwww.sonomapharma.com

Phone707-283-0550

Debt

Debt-to-Equity Ratio0.01%

Current Ratio4.62%

Quick Ratio3.83%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.82 million

Price / Sales1.46

Cash FlowN/A

Price / CashN/A

Book Value$5.00 per share

Price / Book0.79

Profitability

EPS (Most Recent Fiscal Year)($2.03)

Net Income$9.27 million

Net Margins-70.46%

Return on Equity-70.95%

Return on Assets-57.86%

Miscellaneous

Employees243

Outstanding Shares4,740,000

How to Become a New Pot Stock Millionaire

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals (NASDAQ:SNOA) released its earnings results on Wednesday, February, 7th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.10. The company earned $4.84 million during the quarter, compared to analysts' expectations of $4.50 million. Sonoma Pharmaceuticals had a negative return on equity of 70.95% and a negative net margin of 70.46%. View Sonoma Pharmaceuticals' Earnings History.

What price target have analysts set for SNOA?

2 Wall Street analysts have issued twelve-month price targets for Sonoma Pharmaceuticals' stock. Their predictions range from $7.00 to $10.00. On average, they expect Sonoma Pharmaceuticals' share price to reach $8.50 in the next twelve months. View Analyst Ratings for Sonoma Pharmaceuticals.

What are Wall Street analysts saying about Sonoma Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sonoma Pharmaceuticals stock:

1. According to Zacks Investment Research, "Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. " (4/5/2018)
2. Maxim Group analysts commented, "Sonoma reported strong sequential growth (F3Q18) with gross revenues of $4.8M driven by US and Latin America, up 46% versus the same period a year ago. US Dermatology was $2.2M up 78% versus last year. New products were a key driver of growth for the company. Net revenues were $2.9M, also showing strong growth at the prescribers level. The impact of 30 sales reps and five senior managers is manifesting as top line revenues. US revenues now represent more than 2/3 of all revenues with solid margins. The company closed the quarter with $8.6M in cash on the balance sheet." (2/8/2018)

Who are some of Sonoma Pharmaceuticals' key competitors?

Some companies that are related to Sonoma Pharmaceuticals include Evoke Pharma (EVOK), PLx Pharma (PLXP), Chiasma (CHMA), Edge Therapeutics (EDGE), Lipocine (LPCN), Egalet (EGLT), OvaScience (OVAS), Kitov Pharma (KTOV), Pernix Therapeutics (PTX), Jaguar Health (JAGX), Innovus Pharmaceuticals (INNV), AEterna Zentaris (AEZS), Concordia International (CXRX), Tonix Pharmaceuticals (TNXP), IntelliPharmaCeutics Intl (IPCI), Regenerx Biopharmaceuticals (RGRX), Akari Therapeutics (AKTX) and ContraVir Pharmaceuticals (CTRV).

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the folowing people:

Mr. James Schutz, Pres, CEO & Director (Age 55)
Mr. Robert E. Miller, Corp. Sec., CFO & COO (Age 76)
Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 54)
Dr. Robert Northey Ph.D., Director of R&D (Age 61)
Mr. Dan McFadden, VP of Public and Investor Relations

Has Sonoma Pharmaceuticals been receiving favorable news coverage?

News coverage about SNOA stock has trended somewhat negative on Sunday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sonoma Pharmaceuticals earned a news impact score of -0.02 on Accern's scale. They also gave headlines about the company an impact score of 46.38 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $3.94.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $18.69 million and generates $12.82 million in revenue each year. The company earns $9.27 million in net income (profit) each year or ($2.03) on an earnings per share basis. Sonoma Pharmaceuticals employs 243 workers across the globe.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]

MarketBeat Community Rating for Sonoma Pharmaceuticals (SNOA)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		134 (Vote Outperform)
Underperform Votes:		121 (Vote Underperform)
Total Votes:		255

MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Sonoma Pharmaceuticals (NASDAQ:SNOA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Sonoma Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.50, suggesting that the stock has a possible upside of 115.74%. The high price target for SNOA is $10.00 and the low price target for SNOA is $7.00. There are currently 2 hold ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Buy
Consensus Rating Score:	2.00	2.00	2.50	3.00
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$8.50	$8.50	$10.50	$10.00
Price Target Upside:	115.74% upside	120.21% upside	116.94% upside	46.63% upside

Sonoma Pharmaceuticals (NASDAQ:SNOA) Consensus Price Target History

Price Target History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/5/2018	Maxim Group	Downgrade	Buy -> Hold	$7.00	Low
12/28/2017	Benchmark	Initiated Coverage	Speculative Buy -> Speculative Buy	$10.00	High

(Data available from 4/22/2016 forward)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Earnings History and Estimates Chart

Earnings by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.86 EPS
Next Year EPS Consensus Estimate: $-2.2 EPS

Sonoma Pharmaceuticals (NASDAQ SNOA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/7/2018	Q3 2018	($0.63)	($0.73)	$4.50 million	$4.84 million	View	N/A
11/9/2017	Q2 2018	($0.75)	($0.67)	$3.94 million	$4.33 million	View	N/A
8/8/2017	Q1 2018	($0.73)	($0.82)		$3.84 million	View	Listen
6/5/2017	Q4 2017	($0.67)	($0.69)		$4.03 million	View	Listen
2/9/2017	Q3 2017	$3.08	$3.84		$3.36 million	View	Listen
11/10/2016	Q2 2017		($0.46)		$4.11 million	View	N/A
7/28/2016	Q1 2017		($0.61)		$3.81 million	View	N/A
6/16/2016	Q4		($0.16)		$3.53 million	View	Listen
2/4/2016	Q216	($0.07)	($0.19)	$3.56 million	$3.80 million	View	Listen
11/5/2015	Q2 2016	($0.70)	($0.55)	$3.76 million	$4.05 million	View	N/A
7/30/2015	Q116	($0.10)	($0.15)	$3.96 million	$3.70 million	View	Listen
6/11/2015	Q215	($0.25)	($0.11)	$3.12 million	$3.98 million	View	Listen
2/12/2015	Q115	($0.18)	($0.69)	$3.10 million	$3.22 million	View	Listen
11/13/2014	Q2 2015	($0.95)	($0.85)	$3.21 million	$3.26 million	View	N/A
8/7/2014	Q1 15	($0.17)	($0.01)	$3.13 million	$3.39 million	View	N/A
6/12/2014	Q4 14	($0.21)	$0.99	$3.42 million	$2.91 million	View	N/A
2/13/2014	Q3 2014	($0.80)	($1.60)	$3.82 million	$3.29 million	View	N/A
11/19/2013	Q2	($0.15)	($0.21)	$4.03 million	$4.10 million	View	Listen
8/8/2013	Q1 2014	($0.26)	($0.26)	$3.68 million	$3.37 million	View	N/A
6/13/2013	Q4 2013	($0.55)	($1.35)	$3.85 million	$3.34 million	View	N/A
2/13/2013	Q3 2013	($0.08)	($0.05)	$3.28 million	$3.50 million	View	N/A
11/1/2012	Q312	$0.03	($0.05)	$5.59 million	$4.50 million	View	N/A
8/2/2012	Q1 2013	($1.75)	($0.70)			View	N/A
6/7/2012	Q4 2012	($2.45)	($2.17)			View	N/A
2/2/2012	Q3 2012	($1.75)	($3.39)			View	N/A
11/3/2011	Q2 2012	($2.10)	($1.26)			View	N/A
8/4/2011	Q1 2012	($2.10)	($2.73)			View	N/A
6/2/2011	Q4 2011	($2.45)	($2.13)			View	N/A
2/3/2011	Q3 2011	($2.45)	($2.94)			View	N/A
11/4/2010	Q2 2011		($2.20)			View	N/A
8/5/2010	Q1 2011		($3.18)			View	N/A
6/3/2010	Q4 2010		($1.99)			View	N/A
2/4/2010	Q3 2010		($1.75)			View	N/A
11/5/2009	Q2 2010		($3.25)			View	N/A
8/6/2009	Q1 2010		($4.23)			View	N/A
6/11/2009	Q4 2009		($4.55)			View	N/A
2/12/2009	Q3 2009		($7.28)			View	N/A
11/6/2008	Q2 2009	($14.35)	($15.19)			View	N/A
8/5/2008	Q1 2009	($12.95)	($11.41)			View	N/A
6/11/2008	Q4 2008	($15.75)	($11.79)			View	N/A
2/7/2008	Q3 2008	($14.00)	($14.00)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Sonoma Pharmaceuticals (NASDAQ SNOA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 13.24%

Insider Trading History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ SNOA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2018	Robert E Miller	CFO	Buy	2,400	$3.97	$9,528.00	20,088
3/9/2018	Robert E Miller	CFO	Buy	1,200	$3.90	$4,680.00	20,088
3/8/2018	James J Schutz	CEO	Buy	2,473	$3.99	$9,867.27	35,858
11/29/2017	James J Schutz	CEO	Buy	400	$5.03	$2,012.00	15,829
11/29/2017	Robert E Miller	CFO	Buy	1,790	$5.02	$8,985.80	20,088
11/24/2017	James J Schutz	CEO	Buy	254	$5.05	$1,282.70	15,429
11/21/2017	Robert E Miller	CFO	Buy	2,000	$5.03	$10,060.00	20,088
8/10/2017	James J Schutz	CEO	Buy	929	$5.46	$5,072.34	15,175
8/10/2017	Marc Umscheid	Insider	Buy	600	$5.31	$3,186.00	3,392
8/10/2017	Robert E Miller	CFO	Buy	2,264	$5.30	$11,999.20	20,088
3/9/2017	Robert E Miller	CFO	Buy	750	$7.02	$5,265.00	15,964
3/8/2017	Robert E Miller	CFO	Buy	1,000	$6.93	$6,930.00	15,964
3/6/2017	Marc Umscheid	Insider	Buy	750	$6.82	$5,115.00	750
3/3/2017	James J Schutz	CEO	Buy	800	$6.78	$5,424.00	11,736
12/8/2016	James J Schutz	CEO	Buy	1,000	$4.88	$4,880.00	11,040
12/8/2016	Robert E Miller	CFO	Buy	5,000	$4.86	$24,300.00	15,964
8/15/2016	James J Schutz	CEO	Buy	1,328	$3.66	$4,860.48	6,505
2/25/2016	James J Schutz	CEO	Buy	5,000	$1.00	$5,000.00	25,885
11/17/2014	James J Schutz	CEO	Buy	6,285	$1.78	$11,187.30
8/16/2013	James Schutz	CEO	Buy	5,100	$2.35	$11,985.00	14,600
12/10/2012	Hojabr Alimi	CEO	Buy	5,500	$0.64	$3,520.00
12/7/2012	Hojabr Alimi	CEO	Buy	5,300	$0.65	$3,445.00
11/9/2012	James J Schutz	COO	Buy	13,000	$0.80	$10,400.00

(Data available from 1/1/2013 forward)

Sonoma Pharmaceuticals (NASDAQ SNOA) News Headlines

Source:

Date	Headline
	Sonoma Pharma secures regulatory approvals for four products in the UAE; shares up 5% premarket seekingalpha.com - April 17 at 10:16 AM
	Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products finance.yahoo.com - April 17 at 10:16 AM
	Sonoma Pharmaceuticals (SNOA) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - April 14 at 9:18 AM
	Global Coated Endotracheal Tube Market 2018: Analysis & Forecasts 2017-2023 - ResearchAndMarkets.com www.businesswire.com - April 13 at 3:55 PM
	Maxim Group Analysts Give Sonoma Pharmaceuticals (SNOA) a $10.00 Price Target www.americanbankingnews.com - April 11 at 11:52 PM
	Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharma’s Antimicrobial Post-Therapy Gel finance.yahoo.com - April 9 at 10:36 AM
	Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel www.zacks.com - April 6 at 10:56 AM
	Zacks Investment Research Upgrades Sonoma Pharmaceuticals (SNOA) to "Buy" www.americanbankingnews.com - April 5 at 1:11 PM
	FDA clears Sonoma Pharma's antimicrobial post-therapy gel seekingalpha.com - April 5 at 8:11 AM
	Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel globenewswire.com - April 5 at 8:11 AM
	Sonoma Pharmaceuticals (SNOA) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - March 29 at 12:48 PM
	Sonoma Pharmaceuticals (SNOA) Downgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 28 at 8:12 PM
	Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution finance.yahoo.com - March 27 at 10:27 AM
	Sonoma Pharmaceuticals Inc (SNOA) Given $8.00 Average Target Price by Analysts www.americanbankingnews.com - March 16 at 3:12 AM
	Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018 - GlobeNewswire (press release) globenewswire.com - March 10 at 4:01 PM
	Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018 finance.yahoo.com - March 9 at 12:20 PM
	Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock - GlobeNewswire (press release) globenewswire.com - March 7 at 3:54 PM
	Dawson James Securities Announces Closing of $5 Million Public Offering for Sonoma Pharmaceuticals, Inc. finance.yahoo.com - March 7 at 11:05 AM
	Sonoma Pharmaceuticals (SNOA) Lowered to Hold at Maxim Group www.americanbankingnews.com - March 5 at 3:22 PM
	Reviewing Sonoma Pharmaceuticals (SNOA) and Avid Bioservices (CDMO) www.americanbankingnews.com - March 4 at 12:04 PM
	Sonoma Pharmaceuticals (SNOA) Prices $5 Million Public Offering of Common Stock - StreetInsider.com www.streetinsider.com - March 3 at 3:48 PM
	Health Care Sector Update for 03/02/2018: ZSAN,SNOA,VRNA,DPLO - Nasdaq www.nasdaq.com - March 3 at 3:48 PM
	Sonoma Pharmaceuticals (SNOA) Prices $5 Million Public Offering of Common Stock www.streetinsider.com - March 3 at 10:45 AM
	Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock finance.yahoo.com - March 2 at 10:28 AM
	Sonoma Pharmaceuticals (SNOA) PT Lowered to $7 at Maxim Group - StreetInsider.com www.streetinsider.com - February 14 at 3:21 PM
	Maxim Group Analysts Give Sonoma Pharmaceuticals (SNOA) a $7.00 Price Target www.americanbankingnews.com - February 14 at 1:38 PM
	Sonoma Pharmaceuticals (SNOA) PT Set at $11.00 by Maxim Group www.americanbankingnews.com - February 11 at 12:30 PM
	Sonoma Pharmaceuticals' (SNOA) CEO James Schutz on Q3 2018 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - February 8 at 5:38 AM
	Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year ... - GlobeNewswire (press release) globenewswire.com - February 8 at 5:38 AM
	Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% finance.yahoo.com - February 8 at 5:38 AM
	Analysts Expect Sonoma Pharmaceuticals Inc (SNOA) to Announce ($0.63) EPS www.americanbankingnews.com - February 5 at 9:46 AM
	Sonoma Pharmaceuticals (SNOA) versus Syros Pharmaceuticals (SYRS) Head-To-Head Contrast www.americanbankingnews.com - February 2 at 2:22 PM
	Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call finance.yahoo.com - February 2 at 5:43 AM
	Zacks: Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Consensus Target Price by Analysts www.americanbankingnews.com - January 31 at 5:12 PM
	Head to Head Analysis: Sonoma Pharmaceuticals (SNOA) & Synlogic (SYBX) www.americanbankingnews.com - January 30 at 3:18 AM
	Analyzing Sonoma Pharmaceuticals (SNOA) & Cesca Therapeutics (KOOL) www.americanbankingnews.com - January 27 at 11:26 AM
	Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call - Nasdaq www.nasdaq.com - January 26 at 5:46 AM
	Zacks Investment Research Lowers Sonoma Pharmaceuticals (SNOA) to Hold www.americanbankingnews.com - January 18 at 3:16 PM
	Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Average Price Target by Brokerages www.americanbankingnews.com - January 12 at 3:42 AM
	Critical Comparison: Sonoma Pharmaceuticals (SNOA) versus Optimer Pharmaceuticals (OPTR) www.americanbankingnews.com - January 11 at 9:34 AM
	Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis finance.yahoo.com - January 9 at 10:34 AM
	Sonoma Pharmaceuticals (SNOA) Cut to "Hold" at Zacks Investment Research www.americanbankingnews.com - January 5 at 8:10 PM
	Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018 finance.yahoo.com - January 1 at 10:29 AM
	Financial Contrast: Sonoma Pharmaceuticals (SNOA) versus BioMarin Pharmaceutical (BMRN) www.americanbankingnews.com - December 29 at 8:16 AM
	Benzinga's Top Upgrades, Downgrades For December 28, 2017 - Benzinga www.benzinga.com - December 28 at 1:06 PM
	Sonoma Pharmaceuticals (SNOA) Receives New Coverage from Analysts at Benchmark www.americanbankingnews.com - December 28 at 8:18 AM
	Sonoma Pharmaceuticals, Inc. (SNOA) Given $11.00 Average Target Price by Brokerages www.americanbankingnews.com - December 22 at 9:20 PM
	Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis finance.yahoo.com - December 13 at 11:05 AM
	Comparing 3SBio (SSRX) & Sonoma Pharmaceuticals (SNOA) www.americanbankingnews.com - December 10 at 11:34 PM
	Does Sonoma Pharmaceuticals Inc’s (SNOA) Recent Track Record Look Strong? finance.yahoo.com - November 30 at 11:21 AM

Sonoma Pharmaceuticals (NASDAQ:SNOA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Sonoma Pharmaceuticals (NASDAQ:SNOA) Income Statement, Balance Sheet and Cash Flow Statement

Sonoma Pharmaceuticals (NASDAQ SNOA) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff